ZNF217 Activators are a set of chemical compounds designed to specifically increase the functional activity of the ZNF217 protein, a zinc-finger transcription factor encoded by the ZNF217 gene. These activators work through diverse biochemical mechanisms to enhance the transcriptional regulatory roles of ZNF217, which typically include gene expression modulation related to cellular proliferation and survival. A common strategy among these activators is to facilitate the binding affinity and stability of ZNF217 at target gene promoters, which could involve altering the local chromatin structure to a more transcriptionally active state. Some activators may operate by modulating the post-translational modifications of ZNF217, such as phosphorylation or ubiquitination, thereby stabilizing the protein and prolonging its presence in the nucleus. Other compounds might influence the interaction between ZNF217 and other cofactors or components of the transcriptional machinery, enhancing the assembly of transcriptional complexes at specific genomic loci.
Furthermore, ZNF217 Activators may also impact the signaling pathways that converge on the ZNF217 protein's activity. For instance, certain small molecule activators could indirectly enhance ZNF217 function by inhibiting negative regulators or by neutralizing proteins that compete with ZNF217 for binding at target DNA regions. This could result in an upregulation of genes under ZNF217 control, effectively amplifying its regulatory impact on the cellular processes governed by these genes. Additionally, some activators might modulate the cellular concentration of second messengers or alter the activity of kinases and phosphatases that target ZNF217 or its interacting partners. By precisely tuning the cellular signaling milieu, these activators ensure that ZNF217 can execute its transcriptional duties with greater efficiency, leading to a more pronounced biological outcome in line with ZNF217's role in gene expression regulation. The collective actions of these compounds serve to bolster ZNF217's activity without altering its expression levels, thereby harnessing the inherent genetic program of the cell to achieve an enhanced functional state.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
This DNA methyltransferase inhibitor may upregulate genes by demethylation, which could result in an increased binding of ZNF217 to its target gene promoters. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
As a histone deacetylase inhibitor, Trichostatin A can increase acetylation of histones, potentially creating a more accessible chromatin structure for ZNF217 to bind its target genes. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium butyrate, another histone deacetylase inhibitor, may enhance the chromatin binding of ZNF217 by increasing histone acetylation levels. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine is a cytidine analog that can cause DNA demethylation, potentially facilitating ZNF217's binding to its target promoters by altering the methylation status. | ||||||
Cholecalciferol | 67-97-0 | sc-205630 sc-205630A sc-205630B | 1 g 5 g 10 g | $71.00 $163.00 $296.00 | 2 | |
Vitamin D3 through its active metabolite, calcitriol, interacts with the vitamin D receptor, modulating gene expression in a way that could enhance ZNF217 activity. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $63.00 $182.00 | 8 | |
Estradiol binds to estrogen receptors, which may interact with ZNF217, potentially enhancing its activity in estrogen-responsive gene regulation. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
By increasing cAMP levels, Forskolin can activate PKA, which may phosphorylate proteins that interact with ZNF217, thereby potentially enhancing its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY294002 might increase the activity of ZNF217 by affecting downstream signaling pathways that interact with ZNF217. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which can influence the cellular environment in a way that may enhance the activity of ZNF217 by modulating the translation of proteins that interact with ZNF217. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
This Hsp90 inhibitor may disrupt chaperone-mediated protein folding, possibly leading to an enhanced functional activity of ZNF217 through altered interactions with other proteins. | ||||||